Surging Activase sustaining its clinical impact

Activase's market share began rising in April, after the 41,021-patient GUSTO study results indicated that patients given accelerated treatment with tPA plus heparin had 6.3 percent mortality compared with 7.3 percent

Read the full 314 word article

How to gain access

Continue reading with a
two-week free trial.